Clinical Trial Update: Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fractionated gemtuzumab ozogamicin followed by non-engraftment donor leukocyte infusions in relapsed/refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: Brown University | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING